Maximum Royalty Payments Made Before Royalty Interest Reverts Back
Ionis Pharmaceuticals·Products & Services·1 segment
Breakdown
Segments
SpinrazaView metric
| Segment | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Spinraza | $550M | $550M | $550M | $550M | $550M | $550M | $550M | $550M |
| Total | $550M | $550M | $550M | $550M | $550M | $550M | $550M | $550M |